Análisis de minimización de costes de trastuzumab intravenoso frente a trastuzumab subcutáneo para el tratamiento del cáncer de mama metastásico y el cáncer de mama precoz HER2+.

Authors: Gea S, Santiago B, Aceituno S

Year: 2019

Congress: 7 º Congreso de Oncología Médica, Hematología y Farmacia Oncohematológica. Tendiendo puentes

Download PDF

Subscribe to Outcomes´10

Name *

E-mail *

Todos los campos marcados con un * son obligatorios

Responsible for the data: Outcomes'10, s.l.u., Purpose: Sending commercial communications. Legitimation: Art. 6.1 Consent of the interested party. Recipient: No data is transferred unless expressly authorised. You may exercise your rights on data protection (access, rectification, opposition, deletion, automated decisions, limitation of treatment, portability) by email at dpo@outcomes10.com. Data will be retained for the time necessary to fulfill its purpose and derived responsibilities by current regulations and the deadlines in the applicable regulations on archives and documentation. In any case, you can request the protection of the Spanish Data Protection Agency through its website www.aepd.es/. In addition, you can consult more information on the privacy policy

I have read and accepted the privacy policy